Researchers will use a technique called single-cell RNA sequencing to identify surface markers specific to canine hemangiosarcoma cells as a first step toward the development of a more effective and precise therapy.

Researchers are studying if hemangiosarcoma subtypes influence how affected dogs respond to treatment – a step toward precision medicine for these patients.

This study will characterize the expression of toll-like receptors, which activate the immune system, in canine osteosarcoma cells to better determine the biological consequences associated with activating these receptors.

Using genotyping data from the Golden Retriever Lifetime Study, researchers will conduct a study to help identify genomic regions involved with increased susceptibility for hemangiosarcoma in American golden retrievers.

Researchers will standardize and improve organization of data collected from 3,000+ dogs enrolled in Morris Animal Foundation’s Golden Retriever Lifetime Study to expand access and research opportunities.

Researchers are studying the feasibility of an adjunct immunotherapy for large- and giant-breed dogs with osteosarcoma that are not good candidates for cancer surgery or limb amputation.

Researchers will study the frequency of, and risk factors for, cancer in golden retrievers, using data from the Golden Retriever Lifetime Study and VetCompass health databases.

Researchers will study changes in microRNAs in the blood of dogs enrolled in the Golden Retriever Lifetime Study and diagnosed with hemangiosarcoma to identify early disease biomarkers.

Researchers are exploring if a protein found in some human cancers is also present in hemangiosarcoma tumors, and is a feasible therapy target.